GH Research PLC (GHRS)
After hours:
| Previous close | 12.73 |
| Open | 12.81 |
| Bid | 12.29 x 100 |
| Ask | 12.64 x 300 |
| Day's range | 12.30 - 13.04 |
| 52-week range | 5.05 - 14.64 |
| Volume | |
| Avg. volume | 94,679 |
| Market cap | 655.554M |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.62 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 32.00 |
ZacksRecent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
GH Research (GHRS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
ZacksWall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 166.9% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GlobeNewswireGH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3 2024Cash, cash equivalents, other financial assets and marketable securities of $214.0 million expected to provide cash runway into 2026 DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (
